Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03383198 · ClinicalTrials.gov registry record · Phase 4
Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery
A Phase 4 study, sponsored by Prisma Health-Upstate.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03383198: Clinical Trial Phase 4 study, sponsored by Prisma Health-Upstate.
NCT03383198 is a Phase 4 study that was terminated before completion, run by Prisma Health-Upstate. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03383198, a Phase 4 study, was terminated before completion, sponsored by Prisma Health-Upstate.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a randomized controlled pilot study evaluating length of pain control with either liposomal bupivacaine or with bupivacaine plus decadron after PEC II injection in patients having bilateral mastectomies with immediate reconstruction.
Primary Outcome
Subjective, binary question "Does one side of your chest have more surgical pain than the other?"
Interventions
- DRUG Liposomal bupivacaine right injection
- DRUG Liposomal bupivacaine left injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-12-01 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 4 |
Why NCT03383198 stopped before completion
NCT03383198 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Liposomal bupivacaine right injection is the first listed.
NCT03383198 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03383198 about?
NCT03383198 is a clinical study titled "Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery". This is a randomized controlled pilot study evaluating length of pain control with either liposomal bupivacaine or with bupivacaine plus decadron after PEC II injection in patients having bilateral mastectomies with immediate reconstruction.
What is the current status of trial NCT03383198?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2017-12-01. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03383198?
The interventions under investigation include: Liposomal bupivacaine right injection (DRUG), Liposomal bupivacaine left injection (DRUG).
Who is sponsoring clinical trial NCT03383198?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03383198's enrollment target sits among peer trials
5 1989th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI